ClinicalTrials.gov
public full text
Public Domain
Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy
This is a phase 2, open-label, single-arm study of sacituzumab tirumotecan in neuroendocrine prostate cancer (NEPC) with progression after platinum-based chemotherapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer#1185446
- FACBC Prostate Therapy Response#1057259
- Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer.#1203212
- Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors#1044906
- Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer#321703
Record · ID 1214431
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive